Oruka Therapeutics, Inc.: Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing
Oruka Therapeutics (ORKA) reported positive Week 28 data from its EVERLAST-A trial of ORKA-001, showing PASI 100 and PASI 90 rates increased to 71.4% and 87.3%, respectively, without additional dosing. The drug maintained a favorable safety profile. Full 52-week data is expected in December 2026, with 16-week EVERLAST-B data due in 4Q 2026.
How this was made
The 30-second read
Why it matters
The Week 28 data provide the first clear evidence of durable, deep skin clearance without additional dosing, a key differentiator in the market.
Market read
Positive Phase 2a results could catalyze a price rally for ORKA and influence valuation of similar biotech candidates.
What to watch
Potential manufacturing scale‑up challenges and reimbursement uncertainties for a twice‑yearly dosing schedule.
Background
Oruka Therapeutics (Nasdaq: ORKA) is a clinical‑stage biotech developing IL‑23p19 antibodies for psoriasis and hidradenitis suppurativa.
Ticker impact
Oruka Therapeutics announced positive Week 28 Phase 2a data for ORKA-001, showing PASI 100 rates of 71.4% and PASI 90 rates of 87.3% without dosing after Week 4.
Potential upside of 10‑15% in the near term as investors price in the deepening responses.
Phase 2a data are material for a clinical‑stage biotech; the results exceed expectations and suggest a differentiated dosing regimen.
Market effects
May lift other IL‑23p19 competitors and broader psoriasis‑treatment stocks.
Positive for US biotech sector; limited immediate effect elsewhere.
Highlights US biotech innovation in dermatology, could attract global investor interest.
Counterpoint
Long‑term efficacy and safety still need confirmation in Phase 2b and Phase 3; early hype could be premature.
Key entities
- CompanyOruka Therapeutics, Inc.
Developer of ORKA-001, a half‑life extended IL‑23p19 monoclonal antibody.
- ExecutiveJoana Goncalves
Chief Medical Officer of Oruka, quoted on the data.
